Wellington Management Group LLP Boosts Stock Holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX)

Wellington Management Group LLP boosted its position in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) by 5.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 132,895 shares of the company’s stock after buying an additional 6,550 shares during the period. Wellington Management Group LLP owned 0.23% of TScan Therapeutics worth $404,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. SG Americas Securities LLC grew its position in shares of TScan Therapeutics by 31.2% in the fourth quarter. SG Americas Securities LLC now owns 20,415 shares of the company’s stock valued at $62,000 after purchasing an additional 4,852 shares in the last quarter. Wells Fargo & Company MN grew its position in shares of TScan Therapeutics by 41.1% in the fourth quarter. Wells Fargo & Company MN now owns 19,540 shares of the company’s stock valued at $59,000 after purchasing an additional 5,694 shares in the last quarter. Woodline Partners LP grew its position in shares of TScan Therapeutics by 6.7% in the fourth quarter. Woodline Partners LP now owns 115,866 shares of the company’s stock valued at $352,000 after purchasing an additional 7,282 shares in the last quarter. Barclays PLC grew its position in shares of TScan Therapeutics by 16.3% in the fourth quarter. Barclays PLC now owns 67,508 shares of the company’s stock valued at $206,000 after purchasing an additional 9,441 shares in the last quarter. Finally, Prudential Financial Inc. purchased a new stake in shares of TScan Therapeutics in the fourth quarter valued at approximately $32,000. 82.83% of the stock is currently owned by hedge funds and other institutional investors.

TScan Therapeutics Trading Up 7.1%

Shares of TScan Therapeutics stock opened at $1.80 on Friday. The firm has a market capitalization of $101.86 million, a price-to-earnings ratio of -1.70 and a beta of 0.98. TScan Therapeutics, Inc. has a fifty-two week low of $1.02 and a fifty-two week high of $9.29. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56. The stock has a 50 day moving average of $1.41 and a 200 day moving average of $2.21.

TScan Therapeutics (NASDAQ:TCRX) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.02. The company had revenue of $2.17 million during the quarter, compared to analyst estimates of $1.62 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. As a group, research analysts predict that TScan Therapeutics, Inc. will post -1.12 earnings per share for the current year.

Insider Buying and Selling

In other news, major shareholder Lynx1 Capital Management Lp purchased 1,200,000 shares of the firm’s stock in a transaction on Tuesday, May 20th. The shares were bought at an average cost of $1.20 per share, for a total transaction of $1,440,000.00. Following the completion of the purchase, the insider now directly owns 7,946,141 shares of the company’s stock, valued at approximately $9,535,369.20. This trade represents a 17.79% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 4.35% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

TCRX has been the subject of a number of analyst reports. Needham & Company LLC restated a “buy” rating and issued a $9.00 price target on shares of TScan Therapeutics in a research report on Tuesday, April 8th. HC Wainwright dropped their price target on TScan Therapeutics from $15.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. Barclays dropped their price target on TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating for the company in a research report on Friday, March 7th. Wedbush restated an “outperform” rating and issued a $7.00 price target on shares of TScan Therapeutics in a research report on Tuesday, May 6th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $10.00 price objective on shares of TScan Therapeutics in a research report on Friday, March 14th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $7.80.

TScan Therapeutics Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.